Sensei Biotherapeutics, Inc. (SNSE)
| Market Cap | 39.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.09M |
| Shares Out | 1.34M |
| EPS (ttm) | -16.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,680 |
| Open | 30.93 |
| Previous Close | 31.54 |
| Day's Range | 26.47 - 31.45 |
| 52-Week Range | 5.25 - 36.76 |
| Beta | -0.10 |
| Analysts | Strong Buy |
| Price Target | 65.00 (+121.45%) |
| Earnings Date | May 8, 2026 |
About SNSE
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for SNSE stock is "Strong Buy." The 12-month stock price target is $65.0, which is an increase of 121.45% from the latest price.
News
Sensei Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Faeth presented updates on its multi-node cancer metabolism strategy, highlighting strong efficacy and safety data for its oral PIKTOR regimen in endometrial, ovarian, and breast cancers. Key data readouts are expected in 2026–2027, with a focus on expanding indications and maintaining a robust patent position.
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16...
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth...
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Sensei's Board of Directors granted a new employee an option to purchase 166,435...
Sensei Biotherapeutics Transcript: M&A announcement
The acquisition combines expertise in multi-node cancer therapies and computational biology, supported by a $200 million private placement. The deal strengthens the pipeline for difficult-to-treat cancers and positions the company for growth, with integration led by Faeth's former CEO.
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-nod...
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immun...
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics f...
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics f...
Sensei Biotherapeutics Transcript: KOL Event
Solnestretug, a pH-selective VISTA antibody, demonstrated durable responses and a favorable safety profile in PD1-resistant tumors, supporting advancement to phase II trials in lung cancer and Merkel cell carcinoma. The agent’s unique mechanism and tolerability address key unmet needs.
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics f...
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...
Sensei Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Solnerstotug, a VISTA-targeted therapy, showed promising efficacy and safety in PD-L1 resistant tumors, with durable responses and a favorable safety profile. Full phase I/II data will be presented at ESMO in October, and phase II trials are planned for 2026.
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasd...
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics...
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics f...
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06...
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population -
Sensei Biotherapeutics Transcript: Study Update
Solnerstotug, a tumor-selective VISTA antibody, showed promising early efficacy and durable responses in PD-1/PD-L1-resistant hot tumors, with a favorable safety profile and manageable low-grade CRS. Plans are underway for phase II trials and biomarker-driven patient selection.
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing –
Sensei Biotherapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
Solnerstotug, a conditionally active VISTA antibody, has shown promising safety and early efficacy in hot tumors, overcoming prior class limitations. Dose expansion is underway, with a key efficacy milestone expected in Q2, focusing on tumor shrinkage and patient retention.
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics f...
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherap...